Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Identifieur interne : 001809 ( Main/Corpus ); précédent : 001808; suivant : 001810Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Auteurs : Han Zhong ; Yan Wang ; Zai-Li Zhang ; Yang-Xi Liu ; Ke-Jia Le ; Min Cui ; Yue-Tian Yu ; Zhi-Chun Gu ; Yuan Gao ; Hou-Wen LinSource :
- Pharmacological research [ 1096-1186 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Severe Acute Respiratory Syndrome.
- COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I2 = 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I2 = 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority.
DOI: 10.1016/j.phrs.2020.104872
PubMed: 32360583
PubMed Central: PMC7192121
Links to Exploration step
pubmed:32360583Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.</title>
<author><name sortKey="Zhong, Han" sort="Zhong, Han" uniqKey="Zhong H" first="Han" last="Zhong">Han Zhong</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China; Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name>
<affiliation><nlm:affiliation>Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zai Li" sort="Zhang, Zai Li" uniqKey="Zhang Z" first="Zai-Li" last="Zhang">Zai-Li Zhang</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Yang Xi" sort="Liu, Yang Xi" uniqKey="Liu Y" first="Yang-Xi" last="Liu">Yang-Xi Liu</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le, Ke Jia" sort="Le, Ke Jia" uniqKey="Le K" first="Ke-Jia" last="Le">Ke-Jia Le</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cui, Min" sort="Cui, Min" uniqKey="Cui M" first="Min" last="Cui">Min Cui</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yu, Yue Tian" sort="Yu, Yue Tian" uniqKey="Yu Y" first="Yue-Tian" last="Yu">Yue-Tian Yu</name>
<affiliation><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: fishyyt@sina.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gu, Zhi Chun" sort="Gu, Zhi Chun" uniqKey="Gu Z" first="Zhi-Chun" last="Gu">Zhi-Chun Gu</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: guzhichun213@163.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gao, Yuan" sort="Gao, Yuan" uniqKey="Gao Y" first="Yuan" last="Gao">Yuan Gao</name>
<affiliation><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lin, Hou Wen" sort="Lin, Hou Wen" uniqKey="Lin H" first="Hou-Wen" last="Lin">Hou-Wen Lin</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: franklin67@163.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32360583</idno>
<idno type="pmid">32360583</idno>
<idno type="doi">10.1016/j.phrs.2020.104872</idno>
<idno type="pmc">PMC7192121</idno>
<idno type="wicri:Area/Main/Corpus">001809</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001809</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.</title>
<author><name sortKey="Zhong, Han" sort="Zhong, Han" uniqKey="Zhong H" first="Han" last="Zhong">Han Zhong</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China; Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name>
<affiliation><nlm:affiliation>Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zai Li" sort="Zhang, Zai Li" uniqKey="Zhang Z" first="Zai-Li" last="Zhang">Zai-Li Zhang</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Yang Xi" sort="Liu, Yang Xi" uniqKey="Liu Y" first="Yang-Xi" last="Liu">Yang-Xi Liu</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le, Ke Jia" sort="Le, Ke Jia" uniqKey="Le K" first="Ke-Jia" last="Le">Ke-Jia Le</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cui, Min" sort="Cui, Min" uniqKey="Cui M" first="Min" last="Cui">Min Cui</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yu, Yue Tian" sort="Yu, Yue Tian" uniqKey="Yu Y" first="Yue-Tian" last="Yu">Yue-Tian Yu</name>
<affiliation><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: fishyyt@sina.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gu, Zhi Chun" sort="Gu, Zhi Chun" uniqKey="Gu Z" first="Zhi-Chun" last="Gu">Zhi-Chun Gu</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: guzhichun213@163.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gao, Yuan" sort="Gao, Yuan" uniqKey="Gao Y" first="Yuan" last="Gao">Yuan Gao</name>
<affiliation><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lin, Hou Wen" sort="Lin, Hou Wen" uniqKey="Lin H" first="Hou-Wen" last="Lin">Hou-Wen Lin</name>
<affiliation><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: franklin67@163.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmacological research</title>
<idno type="eISSN">1096-1186</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I<sup>2</sup>
= 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I<sup>2</sup>
= 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32360583</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-1186</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>157</Volume>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Pharmacological research</Title>
<ISOAbbreviation>Pharmacol Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>104872</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1043-6618(20)31180-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phrs.2020.104872</ELocationID>
<Abstract><AbstractText>The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I<sup>2</sup>
= 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I<sup>2</sup>
= 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName>
<ForeName>Han</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China; Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Zai-Li</ForeName>
<Initials>ZL</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Yang-Xi</ForeName>
<Initials>YX</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le</LastName>
<ForeName>Ke-Jia</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cui</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Yue-Tian</ForeName>
<Initials>YT</Initials>
<AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: fishyyt@sina.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gu</LastName>
<ForeName>Zhi-Chun</ForeName>
<Initials>ZC</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: guzhichun213@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Yuan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lin</LastName>
<ForeName>Hou-Wen</ForeName>
<Initials>HW</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Electronic address: franklin67@163.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Pharmacol Res</MedlineTA>
<NlmUniqueID>8907422</NlmUniqueID>
<ISSNLinking>1043-6618</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Pharmacol Res. 2020 Oct;160:105055</RefSource>
<PMID Version="1">32619723</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">MERS</Keyword>
<Keyword MajorTopicYN="Y">SARS</Keyword>
<Keyword MajorTopicYN="Y">efficacy</Keyword>
<Keyword MajorTopicYN="Y">safety</Keyword>
<Keyword MajorTopicYN="Y">therapeutic options</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest None conflicts of interest to declare.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32360583</ArticleId>
<ArticleId IdType="pii">S1043-6618(20)31180-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.phrs.2020.104872</ArticleId>
<ArticleId IdType="pmc">PMC7192121</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacotherapy. 2007 Apr;27(4):494-503</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17381375</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Microbiol. 2003 Aug;52(Pt 8):715-720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12867568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2009 Dec;122(12):1150.e11-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19958895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 2008 Jul-Aug;53(4):9-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18756809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104786</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Int Health. 2004 Aug;9(8):923-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15303999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BJGP Open. 2020 Jun 23;4(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32265184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun;92(6):556-563</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jul 15;253:117592</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr;92(4):418-423</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31967327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2018 May;28(3):e1977</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29664167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9835517</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2011 Oct 18;343:d5928</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22008217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2020 May;55:102763</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32361250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):211-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16261199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Dermatolog Treat. 2020 Jun;31(4):322-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32255383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 May;92(5):479-490</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32052466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2013 Aug;57(8):3746-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23716055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2019 Jul - Aug;30:9-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31252170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001809 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001809 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32360583 |texte= Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32360583" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |